Measurement of biochemical markers represents an important aid to clinicians in the earlydiagnosis and prognosis of neurological diseases. Many factors can contribute to increase thechances that a biomarker study becomes successful. In a cerebrospinal fluid analysis (CSF),more than 84% of laboratory errors can be attributed to several preanalytical variables thatinclude CSF collection, storage, and freeze thawing cycles. In this concept paper, we focus onsome critical issues arising from basic proteomics investigation in order to highlight somekey elements of CSF quality control. Furthermore, we propose a direct assessment of samplequality (DASQ) by applying a fast MALDI-TOF-MS methodology to evaluate molecular featuresof sample degradation and oxidation. We propose DASQ as a fast and simple initial step to beincluded in large-scale projects for neurological biomarker studies. In fact, such a procedurewill improved the development of standardized protocols in order to have well-characterizedCSF biobanks.

Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples

Piras C.;Urbani A.
2014-01-01

Abstract

Measurement of biochemical markers represents an important aid to clinicians in the earlydiagnosis and prognosis of neurological diseases. Many factors can contribute to increase thechances that a biomarker study becomes successful. In a cerebrospinal fluid analysis (CSF),more than 84% of laboratory errors can be attributed to several preanalytical variables thatinclude CSF collection, storage, and freeze thawing cycles. In this concept paper, we focus onsome critical issues arising from basic proteomics investigation in order to highlight somekey elements of CSF quality control. Furthermore, we propose a direct assessment of samplequality (DASQ) by applying a fast MALDI-TOF-MS methodology to evaluate molecular featuresof sample degradation and oxidation. We propose DASQ as a fast and simple initial step to beincluded in large-scale projects for neurological biomarker studies. In fact, such a procedurewill improved the development of standardized protocols in order to have well-characterizedCSF biobanks.
2014
Biomarkers
Biomedicine
Cerebrospinal fluid
MALDI-TOF-MS
Neurodegenerative diseases
Sample quality control
Biomarkers
Clinical Chemistry Tests
Humans
Neurodegenerative Diseases
Quality Control
Specimen Handling
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/63322
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? ND
social impact